Beam Therapeutics

EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates

Retrieved on: 
Friday, May 3, 2024
USD, Annual, Alnylam Pharmaceuticals, TTR, Federal Reserve, Agios, BB Biotech, Mitapivat, NAV, Esperies, Accounting, Federal, Cardiomyopathy, NBI, Public expenditure, Prostate cancer, Obesity, Environment, DSM-IV codes, ADC, CRISPR, Patient, Thalassemia, Biotechnology, CRISPR Therapeutics, Initial public offering, Beam Therapeutics, Inflation, CHF, IRA, Drug development, Clinical trial, Significance, Therapy, Pharmaceutical industry

BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates

Key Points: 
  • BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
    The issuer is solely responsible for the content of this announcement.
  • Media release as at April 26, 2024
    Portfolio of BB Biotech AG as at March 31, 2024
    BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
    Investor sentiment in the biotech space continues to be shaped by the general interest rate environment.
  • Net profit for the first quarter of 2024 amounted to CHF 260 mn (net loss of CHF 254 mn in prior-year quarter).
  • While activity in the secondary market has already picked up, there have been few biotech IPOs so far this year.

Nvelop Therapeutics Announces Members of Its Scientific Advisory Board

Retrieved on: 
Thursday, May 2, 2024
Health, Genetics, Other Science, Research, Science, Biotechnology, Harvard University, Danaher Corporation, Novartis, TIL, PACE, Howard Hughes Medical Institute, MIT, Gene therapy, Broad Institute, Gene editing, Duke University, Beam Therapeutics, Microbiology, Faculty, Harvard Medical School, Mammoth Biosciences, Therapy, Thomas Dudley Cabot, Aarhus University, Molecular genetics, Hospital, Arena, Biomedical engineering, RNA, Editas Medicine, Natural science, Bluebird bio, Kite Pharma, Torque, BioMarin Pharmaceutical, Patient, Gene, HSC, Massachusetts General Hospital, Growth, Pharmaceutical industry

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the members of its scientific advisory board, bringing together a world-class group of experts from across the fields of gene therapy, gene editing and drug delivery.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the members of its scientific advisory board, bringing together a world-class group of experts from across the fields of gene therapy, gene editing and drug delivery.
  • Keith Joung, M.D., Ph.D. : Dr. Joung is co-founder of Nvelop Therapeutics, and a pioneer in the development of targeted gene and epigenetic editing technologies.
  • He has co-founded multiple additional biotechnology companies, including Beam Therapeutics, Chroma Medicine, Editas Medicine, Pairwise Plants, SeQure Dx and Verve Therapeutics.
  • He is also the founder or co-founder of several biotechnology and therapeutics companies, including Beam Therapeutics, Prime Medicine, Editas Medicine, Pairwise Plants, Exo Therapeutics and Chroma Medicine.

2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers

Retrieved on: 
Friday, March 22, 2024
Professional Services, Business, Fintech, Training, Start-Up, Technology, Small Business, University, Artificial Intelligence, Education, Biotechnology, Finance, Health, MCAP, Beam Therapeutics, Eli Lilly, Membrane, Innovation, Growth, Insight Partners, Beam, The Ritz-Carlton Hotel Company, GOLD, Blumberg Capital, LYFT, AI, LPCE, Creativity, Senior advisor, Boston College High School, AUM, Former, Summit, Third Rock Ventures, VCG, Sirtris Pharmaceuticals

The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston.

Key Points: 
  • The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston.
  • The Summit is the largest undergraduate entrepreneurship and venture capital conference in the nation and will bring together founders of unicorn startups, CEOs of public companies, and renowned venture capital and private equity investors.
  • The event will convene over 55 speakers and 15 panels on Leadership, Investing, and Entrepreneurship with Advanced Tracks discussing topics ranging from biotech to investing in AI.
  • “For this year’s Entrepreneurship Summit, we are excited to build off of the momentum of last year’s leadership and take it to new heights.

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Beam Therapeutics, Research, PCSK9, American Heart Association, Gene editing, Eli Lilly and Company, Blood, FDA, AHA, N-Acetylgalactosamine, Cardiovascular disease, Food, Verve, Safety, RNA, Vertex Pharmaceuticals, Therapy, Genetics, Lilly, Patient, LPA, Medicine, Clinical trial, ANGPTL3, Apolipoprotein, Science, LDLR, G&A, IND, Asialoglycoprotein receptor, Moyamoya disease, Human, Beam, Pharmaceutical industry

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline updates and financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline updates and financial results for the fourth quarter and year ended December 31, 2023.
  • “2023 was a momentous year for Verve as we made significant strides towards our mission of protecting the world from cardiovascular disease.
  • Verve expects to initiate the VERVE-201 Phase 1b clinical trial in the second half of 2024, subject to regulatory clearances.
  • In October 2023 , Verve announced the expansion of its relationship with Lilly, which was previously established in June 2023.

Third Rock Ventures Expands Senior Team with Seasoned Biotech Executives

Retrieved on: 
Thursday, January 25, 2024
Professional Services, Health, Other Health, Other Science, Finance, Science, Biotechnology, Constellation, Bristol Myers Squibb, Vyasa, Philosophy, Biochemistry, Celgene, Patient, Outline of health sciences, Courtney, Therapy, Thought, Flare, Biology, Partnership, Rutgers University, Third Rock Ventures, GSK, University, Biogen, Harvard University, Tulane University, Economics, MBA, AB, Acquisition, Harvard Business School, Harvard College, IPO, Rock Ventures, Purdue University, Psychology, Ewing Marion Kauffman Foundation, Columbia University, Doctor of Philosophy, Jigar, Kearney (consulting firm), Beam Therapeutics

Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.

Key Points: 
  • Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.
  • Jigar, who joined Third Rock in 2021 as a venture partner, has made significant contributions to the firm’s discovery and company creation activities.
  • Steve Paul, M.D., who has been affiliated with Third Rock since 2010, has re-joined as a venture partner.
  • Prior to Third Rock, Courtney was an early employee and the chief business officer of Beam Therapeutics.

Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors

Retrieved on: 
Tuesday, January 16, 2024
Mental Health, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, New York University, Therapy, Beam, Research, RAPS, Science, Business school, Business, Harvard University, MBA, Citigroup, J. P. Morgan, Beam Therapeutics

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Terry-Ann Burrell to its Board of Directors.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Terry-Ann Burrell to its Board of Directors.
  • Ms. Burrell currently serves as Chief Financial Officer of Beam Therapeutics.
  • “We are very pleased to welcome Ms. Burrell to our board.
  • “This is an important moment for Rapport as the company prepares for both important clinical milestones and the complexities of the biotech financial landscape,” said Ms. Burrell.

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

Retrieved on: 
Monday, January 8, 2024
SCD, LNP, Liver, Beam Therapeutics, Pfizer, Conference, Genotype, Sickle cell disease, Gene editing, Second wave, Survival, ESCAPE, Biotechnology, IND, Research, AAT, Pizzicato, Mortality, G6PC, Therapy, Third wave, Clinical trial, Glucose, DSM-IV codes, GMP, Trial of the century, AATD, Transplant, Growth, Investment, Hematology, Stem cell, HBF, Safety, Liver disease, Piz, CTA, Genetic distance, Beam

CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported progress across the company’s hematology and genetic disease portfolios and provided updates on anticipated upcoming milestones.

Key Points: 
  • “Our vision is to establish Beam as a sustainable, fully integrated company pioneering a new class of genetic medicines with base editing.
  • Preclinical models suggest base editing could lead to improved HbF induction and lower residual disease-causing hemoglobin S compared to existing gene therapy options.
  • The company is on-track to report initial data on multiple patients from the BEACON trial in the second half of 2024.
  • Beam expects to report an initial clinical dataset for BEAM-201 in the second half of 2024.

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

Retrieved on: 
Thursday, December 14, 2023
Beam Therapeutics, Immunology, Lilly, Science, Gene editing, Johnson & Johnson, Biotechnology, Neuroscience, Jan Vansina, MBA, Therapy, Eli Lilly and Company, University, Iowa State University, Beam, Pharmaceutical industry

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company’s board of directors.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company’s board of directors.
  • Prior to Kite, Ms. Shaw served as an executive officer of Eli Lilly and Company (Lilly), a global healthcare company, and president of Lilly Bio-Medicines, the business within Lilly that comprises neuroscience and immunology.
  • She holds a bachelor’s degree in business administration from Iowa State University and an MBA from the University of Wisconsin.
  • I look forward to working alongside such a high-caliber organization and team as we work to bring these innovative therapies to patients.”

Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Science, Apolipoprotein, Primate, FDA, Gene editing, Lilly, United Kingdom, IND, Beam Therapeutics, RNA, Moyamoya disease, Vertex Pharmaceuticals, Frederick, American Heart Association, Host, G&A, Beam, Research and development, Research, R, Mouse, Medicine, Low-density lipoprotein, PCSK9, Blood, General Administration of Sport of China, Safety, ANGPTL3, AHA, Therapy, Administration, ASCVD, Cardiovascular disease, Pharmaceutical industry, Vaccine, Patient, Vertex, Webcast, Verve

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported recent company progress and financial results for the third quarter of 2023.

Key Points: 
  • ET
    BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported recent company progress and financial results for the third quarter of 2023.
  • Verve plans to participate in fireside chats during the following upcoming investor events:
    Cash Position: Verve ended the third quarter of 2023 with $485.2 million in cash, cash equivalents, and marketable securities.
  • Research & Development (R&D) Expenses: R&D expenses were $43.8 million for the third quarter of 2023, compared to $35.2 million for the third quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $11.7 million for the third quarter of 2023, compared to $9.6 million for the third quarter of 2022.

Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3

Retrieved on: 
Tuesday, October 31, 2023
Gene editing, Lilly, Eli Lilly and Company, Beam Therapeutics, Obesity, Moyamoya disease, Beam, Diabetes, CVD, Medicine, Risk, PCSK9, ANGPTL3, Therapy, Patient, ASCVD, Cardiovascular disease, Pharmaceutical industry, Verve

Lilly has acquired from Beam Therapeutics certain product rights to Verve’s cardiovascular in vivo gene editing programs targeting PCSK9 and ANGPTL3, as well as a third undisclosed cardiovascular disease (CVD) target.

Key Points: 
  • Lilly has acquired from Beam Therapeutics certain product rights to Verve’s cardiovascular in vivo gene editing programs targeting PCSK9 and ANGPTL3, as well as a third undisclosed cardiovascular disease (CVD) target.
  • Verve holds all product rights for the PCSK9 and ANGPTL3 programs outside the United States.
  • Verve is a leader in developing gene editing therapies for cardiovascular disease, and we are pleased to expand our relationship with Verve to develop much needed new treatment options for people with cardiovascular disease.”
    This transaction represents an expansion of the relationship between Verve and Lilly.
  • Previously, in June 2023 , Verve and Lilly had entered into an exclusive research collaboration focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a).